<DOC>
	<DOCNO>NCT01427933</DOCNO>
	<brief_summary>This study compare antitumor activity ramucirumab ( IMC-1121B ) eribulin together versus eribulin alone , participant locally recurrent metastatic breast cancer .</brief_summary>
	<brief_title>A Study Ramucirumab ( IMC-1121B ) Combination With Eribulin Versus Eribulin Alone Participants With Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Ramucirumab</mesh_term>
	<criteria>Have histologically cytologically confirm invasive breast cancer time study entry either locally recurrent disease amenable curative therapy Stage IV disease ( American Joint Committee Cancer Staging Criteria breast cancer ) Have measurable and/or nonmeasurable disease per Response Evaluation Criteria Solid Tumors version 1.1 ( RECIST v1.1 ) Have receive least 2 4 prior cytotoxic chemotherapy regimens locally recurrent metastatic setting Have receive prior treatment anthracyclines taxanes , either metastatic , adjuvant neoadjuvant setting Have receive Human Epidermal Growth Factor Receptor 2 ( HER2 ) direct treatment ; candidate HER2directed treatment patient HER2 positive disease Have complete prior radiotherapy and/or hormonal therapy least 1 week prior randomization recover clinically significant treatmentrelated toxicity Have Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 Have leave ventricular ejection fraction within normal limit Have discontinue previous chemotherapy treatment cancer least 3 week prior randomization recover clinically significant toxic effect Have resolution Grade le equal 1 [ National Cancer Institute Common Terminology Criteria Adverse Events ( NCICTCAE ) , Version 4.0 ] clinically significant toxicity prior chemotherapy , surgery , radiotherapy , hormonal therapy exception peripheral neuropathy , must resolve Grade less equal 2 Have adequate hematologic , hepatic , renal , coagulation function Test negative pregnancy Have life expectancy least 3 month Have concurrent active malignancy adequately treat nonmelanomatous skin cancer noninvasive situ neoplasm Are currently enrol , recently discontinue , clinical trial involve investigational product , concurrently enrol type medical research judge medically compatible study Have receive investigational therapy within 3 week prior randomization Have receive prior ramucirumab eribulin Have know sensitivity agent similar biologic composition ramucirumab , halichondrin B and/or halichondrin B chemical derivative Have receive bevacizumab within 6 week prior randomization Have uncontrolled poorly control hypertension Have congenital prolong QTc syndrome ( family history ) prolongation QTc baseline Have history additional risk factor torsades de pointes within last year prior randomization Have implantable pacemaker automatic implantable cardioverter defibrillator Have bradycardia Have acute/subacute bowel obstruction history chronic diarrhea require ongoing medical intervention within 6 month prior randomization Have history uncontrolled hereditary acquire bleed thrombotic disorder Have experience Grade 3 great bleeding event within 3 month prior randomization Have experience Grade 3 great arterial thromboembolic event within 6 month prior randomization , venous thromboembolic event within 3 month prior randomization Have undergone major surgery within 4 week prior randomization subcutaneous venous access device placement within 7 day prior randomization Have plan major surgery perform course trial Have uncontrolled metabolic condition Have ongoing active infection require parenteral antibiotic , antifungal , antiviral therapy Have know human immunodeficiency virus ( HIV ) infection acquire immunodeficiency syndrome ( AIDS ) Have pulmonary lymphangitic involvement result pulmonary dysfunction require active treatment include use oxygen Have receive prior allogeneic organ tissue transplantation Have serious nonhealing wound , ulcer , bone fracture within 4 week prior randomization Have know leptomeningeal metastasis Have cirrhosis ( ChildPugh Level B worse ) cirrhosis ( degree ) history hepatic encephalopathy clinically meaningful ascites</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Breast Cancer</keyword>
</DOC>